In Vivo Imaging of Pigmentary Disorders by Reflectance Confocal Microscopy

Inclusion Criteria: 1. Subjects 20-70 years of age. 2. Clinical diagnosis of vitiligo, melasma, post-inflammatory hypo or depigmentation or post-inflammatory hyperpigmentation. 3. Willing and able to understand and sign informed consent. 4. Able to complete study and comply with study procedures. Exclusion Criteria: 1. Use of topical therapies such as corticosteroids, protopic, hydroquinone and azelaic acid within the past 2 months. 2. Use of light therapy such as narrow-band-UVB, PUVA or laser within the past 2 months. 3. Intake of medications that can cause pigmentary changes within the past year. Examples are: * Antimalarials (chloroquine, hydroxychloroquine) * Chemotherapeutics (bleomycin, busulfan, doxorubicin, daunorubicin, fluorouracil, cyclophosphamide, and carmustine) * Heavy metals (gold, silver, bismuth, and mercury) * Tetracyclines (including minocycline, doxycycline) * Amiodarone * Azidothymidine * Clofazimine 4. Clinically significant abnormal findings or conditions (other than the pigmentary disorder), which might, in the opinion of the Principal Investigator, interfere with study evaluations or pose a risk to subject safety during the study. 5. Subjects who are known to be pregnant or planning a pregnancy.